Sr-PSOX (CXCL16) Mouse Recombinant Protein

CXCL16, a newly discovered CXC chemokine, exists both in a transmembrane and a soluble form. Membrane-bound CXCL16 is expressed by antigen-presenting cells such as monocytes, macrophages, B cells, and dendritic cells in the T- cell zone of lymph nodes. Soluble CXCL16 can be generated by constitutive cleavage from the cell membrane and further enhanced by cell stimulation with phorbol esters. Soluble CXCL16 has been shown to induce chemotaxis of Th1, Tc1, and natural killer T cells, which express the functional CXCR6 receptor. CXCL16 has also been reported as a novel angiogenic factor for human umbilical vein endothelial cells. Moreover, CXCL16 cDNA was shown to be identical to a novel scavenger receptor that binds phosphatidylserine and oxidized lipoprotein. Recently, expression of CXCL16 and/or CXCR6 was shown in nasopharyngeal carcinomas, gliomas, and rectal cancer. Through a cytokine antibody array, we reported that CXCL16 protein production was increased in aggressive prostate cancer cells compared with the less aggressive prostate cancer cells or benign prostate cells.

• eryptotic red blood cell adhesion to vascular endothelium: CXCL16/sr-psox, a pathophysiological amplifier .Am J Physiol Cell Physiol, Dec 2011; 10.1152/ajpcell.00453.2011.
• dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/sr-psox .Am J Physiol Cell Physiol, Dec 2011; 10.1152/ajpcell.00340.2011.
• sr-psox/CXCL16 plays a critical role in the progression of colonic inflammation .Gut, Nov 2011; 60: 1494 - 1505.
• CXCL16 recruits bone marrow-derived fibroblast precursors in renal fibrosis .J. Am. Soc. Nephrol., Oct 2011; 22: 1876 - 1886.
• the CXCL16 a181v mutation selectively inhibits monocyte adhesion to cxcr6 but is not associated with human coronary heart disease .Arterioscler Thromb Vasc Biol, Apr 2011; 31: 914 - 920.